We examined associations between metabolic variables and changes in coronary artery disease (CAD) in the St. Thomas' Atherosclerosis Regression Study (STARS). The course of CAD over 3 years was measured continually by quantitative coronary angiography, i.e., as the per patient change in the mean absolute width of coronary segments (MAWS). The decrease in MAWS (progression of CAD) was significantly correlated with in-trial plasma concentrations of cholesterol (P = 0.002), lowdensity lipoprotein (LDL) cholesterol (P = 0.001), apolipoprotein B (apoB) (P = 0.008), and lipoprotein(a) [Lp(a)] (P = 0.004); no significant associations were found with high-density lipoprotein (HDL) cholesterol, apoA-l, vitamin E, thyroid hormones, fibrinogen, von Willebrand factor, or post-load plasma glucose and insulin concentrations. By multiple regression analysis, LDL cholesterol was the best predictor of IMAWS, the adjusted model explaining 22% of the variance (P = 0.04). Thus, in men with symptomatic CAD the most important metabolic predictor of change in CAD is plasma LDL cholesterol, there being no advantage in measuring other variables, in particular, apoB or Lp(a).
The incidence of coronary artery disease (CAD) is dependent on metabolic factors, the most important of which are probably plasma lipids and lipeproteins (1 )3 Apelipeproteins are the protein components of lipoprotein particles (2), and it has been suggested that plasma concentrations of apolipoprotein (ape) B and apeA are better correlates of CAl) than are low-density lipeproteun (LDL) cholesterol and high-density lipeprotein (HDL) cholesterol, respectively (3, 4). Not all findings have been consistent, however (5,6). Also argued is the strength of the relationship between serum lipoprotein(a) [Lp(a)] and CAD (7) .
Other metabolic variables have also been linked with CAD (8-12). Within populations, plasma glucose or insulin concentrations were shown to predict CAD in nondiabetic subjects (8). Epidemiological data also suggest Departments of Chemical Pathology and Cardiology, St. Thomas (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . In the St. Thomas' Atherosclerosis Regression Study (STARS) (28), we previously showed a significant positive association between plasma LDL cholesterol progression of CAD in middleaged men. Because of the uncertainties mentioned above, in the present study we compared the correlation between change in CAD and LDL cholesterol against a wide spectrum of the metabolic variables, in particular, plasma concentrations of apolipoproteins, Lp(a), vitamin E, vWF, thyroid hormones, and measures of glucose tolerance. Although our principal finding was that LDL cholesterol remained the most powerful predictor of the course of CAD, this result was consistent with the selection of the patients enrolled in STARS and reflected the fact that interventions
were not targeted at changing the plasma concentrations of variables that were not directly related to apeB.
Materials and Methods

Patients and Study Design
Details of the patients, interventions, and study design were as described elsewhere (28 interassay CVs were 3.4%, 4.1%, and 5.8%, respectively. For each patient we recorded the mean of two measurements of the above variables, taken at the mid-point of the trial and at the end.
A standard 75-g oral glucose tolerance test was also carried out half-way through the trial, venous blood being collected into fluoride for the measurement of glucose and into K3-EDTA for insulin. Plasma glucose was assayed by a glucose oxidase method on the Yellow Springs Analyzer (from Clandon Scientific, Aldershot, UK), plasma insulin by ELISA on the ES 700 Analyzer; interassay CVs were 2.2% and 6.5%, respectively.
StatisticalMethods
One-way analysis of variance (ANOVA) and unpaired t-tests were used to compare variables among the three treatment groups and among patients showing progression, no change, or regression of coronary atherosclerosis. Correlations between MAWS and in-trial values of the metabolic variables were examined by univariate linear regression analysis after pooling the data from the three treatment groups. Multiple linear regression with backwards stepwise selection of variables, with a critical P value for entry of 0.1, was used to assess the best predictors of MAWS. Regression equations were adjusted for differences in age, smoking, weight, blood pressure, and treatment group assignment. For this analysis, "treatment group" was entered as two dummy variables. To assess the effects on the course of early and later CAD, we also carried out regression analyses for patients with percentage diameter stenosis 20% and >20% at baseline, the 20% cutoff being the median value.
Results Table 1 shows the plasma concentrations of lipids, lipeproteins, apelipeproteins, vitamin E, fibrinogen, vWF, thyroid hormones, glucose, and insulin in the three treatment groups during the trial. Plasma cholesterol, LDL cholesterol, and apoB concentrations were significantly lower in both intervention groups than in the usual care group. Compared with usual care, the diet group had significantly lower triglyceride (P = 0.01), apoA-I (P = 0.04), vWF (P = 0.04), and 2-h postload glucose (P = 0.03). The diet plus cholestyramine group had significantly lower fibrinogen (P = 0.006) and free triiodothyronine (P = 0.02). There were no significant differences in other variables among the groups. Table 1 . In-trial plasma concentrations of lipids, lipoproteins, apolipoproteins, vitamin E, fibrlnogen, von Willebrand factor, thyroid hormones, glucose, and insulin by treatment group. patients showing progression,  no change, or regressIon of coronary artery dIsease, defined according to global , 26) , the shorter duration of observations or the more powerful effects of heavy physical exercise are possible explanations.
Mean (SEM), by treatment
That adjustment for baseline LDL cholesterol did not significantly influence the association of LMAWS with in-trial LDL cholesterol is compatible with our previous report that the latter is a better predictor of MAWS than is the change in LDL cholesterol (28).
We could not confirm the finding that trilodothyronine independently influences the course of CAD (34) , probably because of the overriding influence of the wider range of plasma cholesterol concentrations in our patients. No prospective angiographic studies have hitherto examined the associations of plasma Lp(a), glucose, insulin, fibrinogen, vWF, or vitamin E with the progression of CAD. In spite of clinical and epidemiological data supporting a role of these variables in increasing the risk of CAD (8) (9) (10) (11) (12) , their effects were not observed in our group of patients; possibly some of these factors play a role in the acute events leading to myocardial infarction rather than in atherosclerosis progression. Our study has possible limitations.
Changes (37) (38) (39) . We have previously demonstrated that the small, dense LDL species correlates best with MAWS (33). LDL cholesterol and apoB are closely correlated, and our data are also consistent with the hypothesis that the uptake of LDL particles by the arterial wall is related to its apoB content (2). In patients with familial combined hyperlipidemia, apoB may be a better predictor of CAD than is LDL cholesterol (3, 23 
